Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2021-12, Vol.35 (12), p.3604-3607
Hauptverfasser:	Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/499 692/699/1541/1990/804 Amyloidosis Biomarkers Biomarkers - blood Brain natriuretic peptide Cancer Research Care and treatment Clinical trials Clinical Trials as Topic Critical Care Medicine Diagnosis Health aspects Hematology Humans Immunoglobulin Light-chain Amyloidosis - blood Immunoglobulin Light-chain Amyloidosis - metabolism Immunoglobulin Light-chain Amyloidosis - pathology Intensive Internal Medicine Letter Measurement Medical prognosis Medicine Medicine & Public Health Natriuretic Peptide, Brain - blood Oncology Patient outcomes Patients Peptide Fragments - blood Peptides Prognosis Retrospective Studies Survival Rate Troponin T - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!